CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10055|
|Brand Name||Avastin (with capecitabine)|
|Indication||Metastatic Colorectal Cancer|
|Funding Request||In combination with capecitabine, for the first-line treatment of advanced or metastatic colorectal cancer (CRC) for patients who are not suitable for oxaliplatin or irinotecan-based therapy|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||No|
|NOC Date||September 5, 2005|
|Manufacturer||Hoffmann-La Roche Limited|
|Sponsor||Cancer Care Ontario Gastrointestinal Disease Site Group|
|Submission Date||February 18, 2015|
|Submission Deemed Complete||February 25, 2015|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||March 4, 2015|
|Check-point meeting||April 20, 2015|
|pERC Meeting||June 18, 2015|
|Initial Recommendation Issued||July 3, 2015|
|Feedback Deadline ‡||July 17, 2015|
|Final Recommendation Issued||July 21, 2015|
|Notification to Implement Issued||August 6, 2015|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.